Less Ads, More Data, More Tools Register for FREE

Pin to quick picksC4XD.L Regulatory News (C4XD)

  • There is currently no data for C4XD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Research update: IL-17

7 Oct 2015 07:00

RNS Number : 4575B
C4X Discovery Holdings PLC
07 October 2015
 



 

Research update: Small molecule leads against IL-17 for inflammation and autoimmune diseases

7 October, 2015 - C4X Discovery Holdings plc ("C4XD"), a leader in rational drug discovery and design, is pleased to provide the following research update on key, highly selective small molecule leads in its programme against Interleukin-17 (IL-17), a critical and high value target in inflammation and autoimmune diseases.

Following the recently announced advances in our diabetes and inflammation programmes, we have shown again that our conformational design technology can significantly outperform conventional drug-discovery approaches when it comes to generating novel agents for challenging disease targets, in this case the member of a protein-protein interaction that has typically proved difficult to target with small-molecule drugs.

IL-17 is implicated in multiple inflammatory and autoimmune diseases and is the subject of numerous clinical studies. Current attempts to target IL-17 are largely based around monoclonal antibodies, which have the necessary size required to inhibit the IL-17/IL-17R engagement. Historically, identifying small molecules that specifically inhibit the IL-17 pathway has been extremely challenging, but our technology has identified small molecules that can selectively block the IL-17/IL-17R interaction with high potency. These are conventional, drug-like compounds, for oral and/or topical use, which would offer benefits over injectable therapies such as IL-17 antibodies. We aim to progress our IL-17 programme towards optimisation and in vivo validation over the coming months.

The first significant market to be targeted by IL-17 antibodies is psoriasis, which is estimated to be worth $6bn per annum. Other significant IL-17 market opportunities include psoriatic arthritis and ankylosing spondylitis, together estimated to be worth a further $6bn per annum.

Outlook

C4XD's most advanced compound, an oral Orexin-1 antagonist for the treatment of addiction, is in formal pre-clinical safety and toxicity studies prior to initiation of clinical trials. C4XD expects to file for regulatory approval of Phase I studies at the end of 2016.

C4XD's programmes against Type 2 Diabetes and Inflammation are progressing towards in vivo proof of concept data, and C4XD expects to be in a position to announce further news regarding these programmes before the end of 2015.

Piers Morgan, CEO of C4XD commented: "We continue to expand our proprietary pipeline by using C4XD's highly effective conformational design technology, and our IL-17 programme is the latest addition. We are rapidly building a portfolio of highly attractive programmes in areas of significant unmet medical need with large target markets. Our technology can be applied broadly to generate drug candidates in a fraction of the time and cost incurred using conventional methods."

--ENDS--

 

For further information please contact:

C4X Discovery Holdings plc

Piers Morgan, CEO 07912 293832

 

Zeus Capital

Dan Bate 0161 831 1512

Dominic Wilson 0203 829 5628

 

FTI Consulting

Matthew Cole / Brett Pollard / Rob Winder / Matthew Moss 020 3727 1000

 

About C4XD

C4XD (AIM: C4XD) is a Manchester-based company focused on optimising drug discovery and design. It was founded in 2008 as a spin-out from the University of Manchester. The company uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. Since C4XD's NMR technology shows what shapes active molecules prefer to adopt, it provides high-quality templates for rational drug discovery and design, and valuable conformational information for drug candidate optimisation. In addition, the data is generated faster and more reliably than standard techniques such as X-ray co-crystallography or molecular modelling. C4XD is using its technology in collaboration with the pharmaceutical industry and to build its own proprietary pipeline of high-value therapeutic candidates. For additional information please go to: www.c4xdiscovery.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKQLFBEBFEFBD
Date   Source Headline
7th Dec 20204:05 pmRNSC4X Discovery Notice of Results
12th Nov 202012:32 pmRNSHolding(s) in Company
12th Nov 202011:36 amRNSHolding(s) in Company
12th Nov 20209:14 amRNSHoldings in Company
11th Nov 20206:12 pmRNSHoldings in Company
11th Nov 20204:44 pmRNSHolding(s) in Company
9th Nov 202011:24 amRNSResult of General Meeting and Issue of Equity
21st Oct 20203:54 pmRNSResult of Placing
21st Oct 20207:06 amRNSProposed Placing
10th Sep 202010:18 amRNSHolding(s) in Company
2nd Sep 202010:19 amRNSHolding(s) in Company
25th Aug 20207:00 amRNSBusiness Update
18th Aug 202011:05 amRNSSecond Price Monitoring Extn
18th Aug 202011:00 amRNSPrice Monitoring Extension
29th Jul 20202:54 pmRNSCancellation and Regrant of Existing Share Options
21st Jul 20202:02 pmRNSHoldings in Company
5th Jun 20207:00 amRNSClive Dix appointed to the UK Vaccine Taskforce
13th May 20203:28 pmRNSHoldings in Company
12th May 20206:23 pmRNSHolding(s) in Company
12th May 20202:02 pmRNSHolding(s) in Company
7th May 202012:36 pmRNSResult of Placing
7th May 20207:00 amRNSProposed Placing
29th Apr 20209:00 amRNSPrice Monitoring Extension
29th Apr 20207:00 amRNSInterim results
28th Apr 20204:41 pmRNSSecond Price Monitoring Extn
28th Apr 20204:37 pmRNSPrice Monitoring Extension
24th Apr 20207:00 amRNSNotice of Results
30th Mar 20202:06 pmRNSSecond Price Monitoring Extn
30th Mar 20202:01 pmRNSPrice Monitoring Extension
31st Jan 202012:24 pmRNSResult of AGM
17th Jan 20209:00 amRNSNotice of AGM and Posting of 2019 Annual Report
7th Jan 20207:00 amRNSFull Year Results
12th Dec 201911:04 amRNSNotice of Full Year Results
9th Dec 20191:20 pmRNSAltasciences appointed by Indivior
5th Dec 20192:24 pmRNSGrant of Options
19th Nov 20193:38 pmRNSDirector Dealings
19th Nov 20197:00 amRNSHoldings in Company
18th Nov 20193:02 pmRNSHoldings in Company
18th Nov 20193:00 pmRNSHoldings in Company
18th Nov 20192:58 pmRNSHoldings in Company
13th Nov 201911:21 amRNSResult of General Meeting
24th Oct 20194:40 pmRNSSecond Price Monitoring Extn
24th Oct 20194:35 pmRNSPrice Monitoring Extension
24th Oct 20194:02 pmRNSResults of Placing
24th Oct 20197:00 amRNSProposed Placing, Subscription and Open Offer
1st Oct 20197:00 amRNSBusiness update
27th Sep 20194:41 pmRNSSecond Price Monitoring Extn
27th Sep 20194:35 pmRNSPrice Monitoring Extension
27th Sep 20199:40 amRNSIndivior awarded NIH HEAL grant for C4X3256
2nd Sep 20197:00 amRNSC4XD forms Drug Discovery Advisory Network

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.